Ubrogepant: Mechanism of action, clinical and translational science
Abstract In recent years, the treatment of migraine has experienced a breakthrough in the development of drugs that target the calcitonin gene‐related peptide (CGRP) signaling pathway. Monoclonal antibodies against the receptor or ligand have been developed for the preventive treatment of migraine;...
Saved in:
Main Authors: | Ramesh Boinpally (Author), Mohamad Shebley (Author), Joel Trugman (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Atogepant: Mechanism of action, clinical and translational science
by: Ramesh Boinpally, et al.
Published: (2024) -
Evaluation of the pharmacokinetic interaction and safety of ubrogepant coadministered with acetaminophen or nonsteroidal anti-inflammatory drugs: A randomized trial
by: Abhijeet Jakate, et al.
Published: (2020) -
Ubrogepant to Treat Acute Migraine in Adults
by: Amber N. Edinoff, et al.
Published: (2021) -
Mobocertinib: Mechanism of action, clinical, and translational science
by: Michael J. Hanley, et al.
Published: (2024) -
Molnupiravir: Mechanism of action, clinical, and translational science
by: Brian M. Maas, et al.
Published: (2024)